Next Article in Journal
Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study
Next Article in Special Issue
α-Conotoxins and α-Cobratoxin Promote, while Lipoxygenase and Cyclooxygenase Inhibitors Suppress the Proliferation of Glioma C6 Cells
Previous Article in Journal
Identification, Purification and Molecular Characterization of Chondrosin, a New Protein with Anti-tumoral Activity from the Marine Sponge Chondrosia Reniformis Nardo 1847
Previous Article in Special Issue
Characterisation of δ-Conotoxin TxVIA as a Mammalian T-Type Calcium Channel Modulator
Article

Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models

E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, 15 Rechkunovskaya Str., 630055 Novosibirsk, Russia
*
Author to whom correspondence should be addressed.
Mar. Drugs 2020, 18(8), 410; https://doi.org/10.3390/md18080410
Received: 2 June 2020 / Revised: 22 July 2020 / Accepted: 27 July 2020 / Published: 2 August 2020
(This article belongs to the Special Issue Ion Channels as Marine Drug Targets)
Several experimental studies have recently demonstrated that temporary autonomic block using botulinum toxin (BoNT/A1) might be a novel option for the treatment of atrial fibrillation. However, the assessment of antiarrhythmic properties of BoNT has so far been limited, relying exclusively on vagal stimulation and rapid atrial pacing models. The present study examined the antiarrhythmic effect of specially formulated BoNT/A1-chitosan nanoparticles (BTN) in calcium chloride-, barium chloride- and electrically induced arrhythmia rat models. BTN enhanced the effect of BoNT/A1. Subepicardial injection of BTN resulted in a significant antiarrhythmic effect in investigated rat models. BTN formulation antagonizes arrhythmia induced by the activation of Ca, K and Na channels. View Full-Text
Keywords: botulinum toxin A1; chitosan nanoparticles; antiarrhythmics; pharmacological models of arrhythmia; electrically induced arrhythmia botulinum toxin A1; chitosan nanoparticles; antiarrhythmics; pharmacological models of arrhythmia; electrically induced arrhythmia
Show Figures

Figure 1

MDPI and ACS Style

Sergeevichev, D.; Fomenko, V.; Strelnikov, A.; Dokuchaeva, A.; Vasilieva, M.; Chepeleva, E.; Rusakova, Y.; Artemenko, S.; Romanov, A.; Salakhutdinov, N.; Chernyavskiy, A. Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models. Mar. Drugs 2020, 18, 410. https://doi.org/10.3390/md18080410

AMA Style

Sergeevichev D, Fomenko V, Strelnikov A, Dokuchaeva A, Vasilieva M, Chepeleva E, Rusakova Y, Artemenko S, Romanov A, Salakhutdinov N, Chernyavskiy A. Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models. Marine Drugs. 2020; 18(8):410. https://doi.org/10.3390/md18080410

Chicago/Turabian Style

Sergeevichev, David, Vladislav Fomenko, Artem Strelnikov, Anna Dokuchaeva, Maria Vasilieva, Elena Chepeleva, Yanina Rusakova, Sergey Artemenko, Alexander Romanov, Nariman Salakhutdinov, and Alexander Chernyavskiy. 2020. "Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models" Marine Drugs 18, no. 8: 410. https://doi.org/10.3390/md18080410

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop